

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3820091

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
L&F HEALTH LLC	12/15/2015
RECEIVING PARTY DATA	
Name:	L&F RESEARCH LLC
Street Address:	175 SW 7TH STREET
Internal Address:	SUITE 1900
City:	MIAMI
State/Country:	FLORIDA
Postal Code:	33130
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14967831
CORRESPONDENCE DATA	
Fax Number:	(703)243-6410
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	703-243-6333
Email:	snowden@mwzb.com
Correspondent Name:	TIMIKA SNOWDEN
Address Line 1:	MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Address Line 2:	2200 CLARENDON BLVD., SUITE 1400
Address Line 4:	ARLINGTON, VIRGINIA 22201
ATTORNEY DOCKET NUMBER:	LFR-0001-D01
NAME OF SUBMITTER:	TIMIKA SNOWDEN
SIGNATURE:	/Timika Snowden/
DATE SIGNED:	04/07/2016
Total Attachments: 1	
source=Assignment-LFHtoLFR#page1.tif	

ASSIGNMENT

In consideration of good and valuable consideration, the receipt of which is acknowledged, L&F Health LLC, a Florida Limited Liability Company, having a business address at 175 SW 7th Street, Suite 1900, Miami FL 33130 (hereinafter, ASSIGNOR), as assignee and owner of 100% interest in certain technology which is the subject of this Assignment, does hereby sell and assign to L&F Research LLC, a Florida Limited Liability Company, having a business address at 175 SW 7th Street, Suite 1900, Miami FL 33130 (hereinafter ASSIGNEE), its successors and assigns, the entire right, title and interest in and to the invention and any and all improvements in the invention directed to the use of cyclodextrins and derivatives thereof for preventing and treating kidney disease or conditions, as defined in original claims 31-36 and 41-45 of International Patent Application Serial No. PCT/US2011/056272, filed October 14, 2011, entitled ASSAYS, METHODS AND KITS FOR PREDICTING RENAL DISEASE AND PERSONALIZED TREATMENT STRATEGIES, and any and all related applications for patent and patents therefor in any and all countries, including all divisions, reissues, continuations and extensions thereof, and specifically including US Patent Application, Ser. No. 14/967,831 filed December 14, 2015 and all claims therein or therefrom, and any foreign counterpart, including any patent application filed in Canada specifically drawn or relating to subject matter corresponding to original claims 31-36 and 41-45 of International Patent Application Serial No. PCT/US2011/056272 and directed to the use of cyclodextrins and derivatives thereof for preventing and treating kidney disease or conditions, and all rights of priority resulting from the filing of said International Patent Application or its parent United States Provisional Patent Application (Ser. No. 61/481,485) filed May 2, 2011, and authorizes and requests any official whose duty it is to issue patents, to issue any patent on said improvements to said ASSIGNEE or its successors or assigns and agrees that on request and without further consideration, but at the expense of said ASSIGNEE, will communicate to said ASSIGNEE, or its representatives or nominees, any facts known to ASSIGNOR respecting said invention or improvements, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing and reissue applications, make all rightful oaths and generally do everything reasonably possible to aid said ASSIGNEE, its successors, assigns, and nominees, to obtain and enforce proper patent protection for said invention or improvements in all countries.

OL
14

Date: Dec 15, 2015

ASSIGNOR:

Oliver Lenz

Dr. Oliver Lenz, President
L&F Health LLC

ACKNOWLEDGED AND ACCEPTED

For ASSIGNEE:

Signature: *Marc A. Golden*
Marc A. Golden, Chief Executive Officer
L&F Research LLC

Date: Dec. 15, 2015

PATENT